Peer-reviewed veterinary case report
Fungal skin infections in dogs on ciclosporin for immune diseases
By Orlandini, Paola et al.·Published in Veterinary dermatology·2026·San Marco Veterinary Clinic and Laboratory, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cutaneous Invasive Opportunistic Fungal Infections in Dogs Receiving Ciclosporin for Immune-Mediated Diseases: A Case-Control Study.
- Species:
- dog
Plain-English summary
A group of dogs receiving a medication called ciclosporin for immune-related diseases developed skin infections caused by fungi. Researchers compared eight dogs with these infections to twenty dogs without them, looking for common factors. They found that dogs with higher neutrophil counts (a type of white blood cell) were more likely to have these fungal infections. However, they didn't find any strong links between the treatment or other factors and the infections. More studies are needed to understand how to better monitor and prevent these infections in dogs on immunosuppressive treatments.
People also search for: dog skin infection treatment · ciclosporin side effects in dogs · why is my dog getting fungal infections
Abstract
BACKGROUND: Cutaneous opportunistic invasive fungal infections (OIFIs) are mainly reported in immunosuppressed dogs, especially those receiving ciclosporin (CsA). Studies investigating factors other than CsA that favour cutaneous OIFIs in dogs are lacking. HYPOTHESIS/OBJECTIVES: To identify host factors, clinicopathological data, and therapeutic regimens associated with the development of cutaneous OIFIs in dogs receiving CsA for immune-mediated diseases. ANIMALS: Client-owned dogs treated with CsA, with or without systemic glucocorticoids (GCs) for various immune-mediated diseases. Dogs were classified as cases if they had developed cutaneous OIFIs during CsA treatment, or as controls if they had not. MATERIALS AND METHODS: Cases and controls were matched based on the immune-mediated disease and the duration of CsA treatment. Signalment, anamnestic and pertinent clinical data as well as selected laboratory parameters, including blood cell count, neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte ratio (NMR), C-reactive protein, haptoglobin, total globulins and immunoglobulin (Ig)G and IgM serum levels, were retrospectively collected and analysed. RESULTS: Eight OIFI-affected dogs were matched with 20 control dogs. Among the examined variables, only higher neutrophil count and neutrophil ratios (NLR, NMR) were significantly associated with cutaneous OIFIs. CONCLUSIONS AND CLINICAL RELEVANCE: No significant associations were observed between host factors, treatment regimens, and OIFI development in dogs receiving CsA. Further research is needed to clarify the role of GCs and to evaluate NLR and NMR as monitoring tools in immunosuppressed dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/42046400/